Tenaya Therapeutics, Inc. (TNYA) is a clinical-stage biotechnology company developing gene therapies for cardiovascular disease. Its lead programs are TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
Across the credible, current targets reviewed, the figures cluster between $2.00 and $8.00. Morgan Stanley and Leerink Partners sit at the low end at $2.00 (Overweight and Outperform, respectively), H.C. Wainwright carries $3.00, LifeSci Capital $4.00, Canaccord Genuity $5.00, and Chardan Capital $8.00. The arithmetic mean of these six targets is $4.00, which is the central target used here. An additional, much higher figure from Piper Sandler ($40.00) was treated as an apparent data-entry error and excluded, given its inconsistency with the rest of the field and the company's size.
The overall posture is bullish but the range is wide, which is typical of pre-commercial biotech. Analysts generally point to the same underlying thesis — encouraging biomarker and safety signals in cardiac gene therapy — but differ sharply on how much clinical progress and commercial potential to underwrite today. Several firms trimmed targets through late 2025 and early 2026, including Morgan Stanley (from $5.00 to $2.00), H.C. Wainwright (from $5.00 to $3.00), and Canaccord Genuity (from $6.00 to $5.00), reflecting a more measured view of near-term catalysts and financing needs.
As of the latest verified close, shares traded near $0.41, toward the lower end of a 52-week range of roughly $0.36 to $1.96, with a market capitalization of about $92 million. Reaching the $4.00 central target from here implies an increase of roughly 875%, a very large move that would require a fundamental re-rating of the company, not merely a technical bounce.
Financially, Tenaya remains pre-revenue in a meaningful sense, reporting trailing revenue of about $1.3 million and a trailing net loss near $103 million, or an EPS (earnings per share) loss of about $0.52. It had roughly $78 million in cash at the most recent quarter. The path toward the target therefore rests almost entirely on clinical execution: additional efficacy and safety readouts from its lead gene therapy programs and eventual clarity on a registrational and commercial path.
Shares sit near the bottom of a 52-week range that extends up to roughly $1.96, after declining sharply over the past year. The $1.00 level represents a psychologically significant round number and a prior trading area that would need to be reclaimed before the stock could mount a sustained advance toward analyst targets. The $2.00 level — the lowest current analyst target — stands as a notable resistance zone, followed by progressively higher targets above it.
Analyst price targets typically reflect a research horizon of about 12 months, though firms apply this differently, and no uniform date applies across the six targets reviewed. Key items to watch include the next earnings report (scheduled around November 11, 2026), additional TN-201 and TN-401 data readouts, guidance on cash runway and any financing activity, and analyst target revisions. These catalysts, rather than day-to-day price action, are most likely to determine whether the stock can close the gap toward higher targets.
For traders monitoring volatile, catalyst-driven names like this one, AI Daily Buy/Sell Signals offers a data-driven complement to fundamental research. The system uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. It can help traders discover new opportunities, keep tabs on existing positions, and spot changing trends more efficiently than manual screening. Explore the tool to see how its signals can sharpen your own market outlook.
The question of whether TNYA can reach $4.00 ultimately comes down to science and execution, not sentiment. The $4.00 central target is the mean of six analyst targets ranging from $2.00 to $8.00, and it implies a very large gain of roughly 875% from the current price near $0.41. Bulls point to promising early gene therapy data and a runway into late 2027; skeptics highlight heavy cash burn, future dilution, clinical uncertainty, and the wide gap between the most conservative and most aggressive targets. Investors should watch data readouts, financing developments, and analyst revisions rather than assume the target is a forecast of what will happen.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TNYA has been loosely correlated with ANIX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TNYA jumps, then ANIX could also see price increases.
| Ticker / NAME | Correlation To TNYA | 1D Price Change % | ||
|---|---|---|---|---|
| TNYA | 100% | -0.56% | ||
| ANIX - TNYA | 43% Loosely correlated | +2.58% | ||
| VCYT - TNYA | 40% Loosely correlated | -0.39% | ||
| ABEO - TNYA | 40% Loosely correlated | -0.89% | ||
| SLDB - TNYA | 38% Loosely correlated | -3.43% | ||
| MIST - TNYA | 37% Loosely correlated | +1.06% | ||
More | ||||